Hypertension is an important risk factor for cardiovascular diseases such as chronic kidney disease. It is still not fully understood how blood pressure impacts the kidneys. In this study, we aimed to establish the significance of visit-to-visit variability in blood pressure for renal function. We analyzed 143 consecutive patients undergoing renal Doppler ultrasonography in our hospital ward and measured blood pressure at outpatient visits six or more times. We analyzed the correlation between visit-to-visit variability in blood pressure and multiple clinical parameters, including albuminuria and resistive index evaluated by renal Doppler ultrasonography, which is thought to be a good indicator of renal vascular resistance. Subjects with higher variability in systolic blood pressure showed a significantly higher prevalence rate of clinical albuminuria and microalbuminuria, and showed significantly higher resistive index. Stepwise multiple regression analysis showed that variability in systolic blood pressure was a significant risk factor for higher resistive index, independent of other renal risk factors. Visit-to-visit variability in blood pressure correlates significantly with renal function and renal arteriosclerotic change. This parameter could provide additional information about renal arteriosclerotic change independent of estimated glomerular filtration rate and albuminuria, and should be considered a therapeutic target for renal protection.
INTRODUCTION
Hypertension is one of the most important treatable risk factors for chronic kidney disease (CKD). 1-2 However, the mechanism by which hypertension influences renal function and produces renal vascular damage is still incompletely understood. Blood pressure (BP) level is widely recognized to strongly correlate with CKD, as it does with other cardiovascular diseases. [3] [4] [5] Clinical guidelines recommend using mean BP, systolic BP (SBP) and diastolic BP (DBP) for diagnosis and management of hypertension to prevent cardiovascular events such as progression of renal dysfunction.
Recently, additional parameters, such as variability in BP, were demonstrated to correlate with cardiovascular events. 6 For example, Rothwell et al. 7 showed that visit-to-visit variability in SBP is a strong predictor of stroke. There are no data available regarding the relationship between renal function and visit-to-visit variability in BP.
The resistive index (RI: (peak systolic velocityÀend diastolic velocity)/peak systolic velocity at segmental arteries in kidney) evaluated by renal Doppler ultrasonography (RDU) is considered a useful index of renal vascular resistance secondary to arteriosclerosis [8] [9] [10] and is a good prognostic indicator of renal function. [11] [12] [13] [14] [15] [16] We previously reported that the RI might be a more efficacious parameter for the evaluation of very early renal damage than estimated glomerular filtration rate (eGFR). 17 It is thought that renal vascular damage caused by atherosclerotic risk factors such as hypertension and variability of BP could be evaluated more precisely by the RI.
In this study, we assessed the hypothesis that visit-to-visit variability in BP correlates significantly with renal function. We investigated the correlation between visit-to-visit variability in BP (expressed as standard deviation (s.d.) and coefficient variant (CV: s.d./mean)) and various renal function parameters such as eGFR, RI and level of proteinuria. We also investigated the correlation between visit-to-visit variability in BP and other biochemical parameters. Figure 1 shows a flow chart of the selection process for study participants. In our hospital ward, almost all admitted patients for several internal diseases, such as diabetes mellitus, hypertension, CKD and so on, undergo RDU to evaluate renal arteriosclerotic change. We initially enrolled 281 consecutive patients with and without CKD undergoing RDU in our hospital ward between February 2009 and May 2011. Patients were excluded if they had renal artery stenosis (n¼16), renal transplant (n¼1) or were on dialysis (n¼1). Of the 263 patients, 120 returned for follow-up visit with BP measurement less than six times; therefore, a total of 143 patients were included in this study. In addition, we analyzed a subgroup of 104 patients who had BP measured at outpatient visits 10 or more times before and/or after RDU examination.
METHODS

Study subjects
Visit-to-visit variability in BP was defined as the s.d. and CV in BP. Variables were calculated from BP measured at six serial visits before and/or after RDU examination.
Subjects underwent biochemical examination of the blood and urine. Clinical parameters considered in this study were: height, weight, body mass index, eGFR, serum lipid profile, fasting blood glucose, glycosylated hemoglobin, hemoglobin A1c, additional biochemical parameters, proteinuria level, SBP and DBP at the time of RDU, smoking history and drug profile. The Clinical Investigations Ethics committee of Osaka University Hospital approved the study protocol. The study was performed in adherence with the principles of the Declaration of Helsinki and according to Good Clinical Practice standards.
Ultrasonographic determination
RI was calculated as:
RI¼(peak systolic velocityÀend diastolic velocity)/peak systolic velocity.
Patients were placed in a supine position, and the size of the left and right kidneys and the flow velocity in the aorta and renal arteries were evaluated to detect morphological abnormality or renal artery stenosis. RI was determined in three different segmental arteries of both kidneys, and expressed as the mean of these values; this method was reported to be identical and technically easy to perform so that reproducibility of RI could be improved. [18] [19] [20] Previous studies indicated that reliable RI measurements depended on proper measuring techniques performed by experienced operators, 21 so in this study Doppler examinations were performed by the three experienced operators (TK, KK and MO) using a XARIO SSA-660A ultrasound machine (TOSHIBA, Tokyo, Japan) with a 2.5-MHz sector transducer.
Renal function
eGFR was calculated using the following equation: eGFR (ml min À1 per1.73 m 2 )¼194ÂcreatinineÀ1.094ÂageÀ0.287 (Â0.739 if female). 22 The level of albuminuria was evaluated according to the American Diabetes Association classification. 23 The albumin/creatinine ratio in spot urine was used to classify proteinuria as follows: no proteinuria: o30 mg g À1 creatinine; microalbuminuria: 30-300 mg g À1 creatinine; clinical albuminuria: Z300 mg g À1 creatinine.
BP measurements
Conventional BP was measured by trained observers with an electronic sphygmomanometer (HEM-705IT or HEM-711; OMRON, Kyoto, Japan). Following the guidelines for the management of hypertension, at every visit (monthly-bimonthly), clinic BP was measured at least two times in sitting position after 5 min rest, and we adopted the average of two readings as office BP if the difference of measured values was o5 mm Hg. When the difference of measured values was more than 5 mm Hg, additional measurements were conducted to obtain stable BP readings and we adopted the average of the two stable readings as office BP.
Statistical analysis
All data are expressed as mean±s.d. Differences between groups were analyzed employing the unpaired Student's t-test and Pearson's w 2 test. Multiple linear regression analysis was performed to determine more related variables for RI.
Stepwise multiple regression analysis was used to identify possible determinants of RI. The level of significance was defined as Po0.05. All statistical analyses were performed using JMP (JMP version 8.0.1, Cary, NC, USA).
RESULTS
This study included 143 consecutive patients who underwent RDU in our hospital ward from February 2009 to May 2011 and who had their BP measured at outpatient visits six or more times before and/or after RDU examination (Figure 1) . Table 1 reports baseline patient characteristics. Mean age was 68.1 ± 13.0 years. In all, 79 patients were women and 64 were men. A total of 133 patients (93.0%) were receiving treatment with antihypertensive agents, including angiotensin receptor blockers, angiotensin-converting enzymes inhibitors, calcium channel blockers, diuretics, b-blockers, a-blockers or aldosterone blockers. In all, 95 patients (66.4%) were receiving two or more different antihypertensive agents; 58 patients (40.8%) were taking statins for dyslipidemia; and 51 patients (35.7%) had type 2 diabetes mellitus. 12.32 ± 5.68, Po0.05; CV in SBP, patients with DM: 0.10 ± 0.04 vs. patients without DM: 0.09 ± 0.04, Po0.05). There were no significant correlations between variability in BP and usage of each antihypertensive agent (angiotensin receptor blockers, angiotensinconverting enzymes inhibitors, calcium channel blocker, diuretics, bblockers, a-blockers or aldosterone blockers).
Secondly, we compared RI, eGFR and level of proteinuria between the quartile of s.d. in SBP and CV in SBP to investigate how variability of BP correlated with renal function. Patients with higher variability in SBP showed a significantly higher prevalence rate of clinical albuminuria and microalbuminuria (Pearson's w 2 test, P¼0.0014) ( Figure 2 ) and a significantly higher RI (Figure 3 ). However, there was no significant correlation between variability in SBP and eGFR.
As Rothwell et al. 7 suggested that risks of stroke and coronary events increased in relation to maximum SBP in outpatient visits, we investigated the correlation between maximum SBP in six outpatients visit and RI, eGFR and proteinuria. RI was significantly correlated with maximum SBP (R¼0.179, Po0.05); however, eGFR was not significantly correlated with maximum SBP (R¼0.080, P¼0.344). Patients with albuminuria or microalbuminuria showed significantly higher maximum SBP (patients with albuminuria or microalbuminuria: 167.5±25.0 vs. patients without albuminuria: 154.6±15.8, Po0.005.)
In the recent article from the NHANES III, BP measured at outpatient visits for three times were analyzed as BP variability, and higher levels of short-term visit-to-visit SBP variability were associated with increased all-cause mortality. 24 Therefore, to further investigate, Figure 1 Flow chart of the selection process of study subjects.
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we analyzed a total of 171 patients with BP measured at outpatient visits three or more times before and/or after RDU examination and calculated s.d. and CV similarly. Subjects with higher variability in SBP from three BP measurements also showed a significantly higher RI with lower decision correlation (Figure 4 ). On the other hand, patients with higher variability in SBP from three BP measurements showed the tendency of higher prevalence rate of clinical albuminuria and microalbuminuria, but there was no significant correlation (data not shown). Multivariate analysis revealed that s.d. in SBP and CV in SBP was significant risk factors for higher RI independent of other renal risk factors. Table 3 
DISCUSSION
This is the first report analyzing the impact of variability in BP on renal function. We showed that visit-to-visit variability in BP was significantly correlated with the level of albuminuria and was a risk factor for higher RI independent of other traditional renal risk factors.
Previous studies revealed that the RI was a useful predictor of renal dysfunctions [11] [12] [13] [14] [15] [16] and correlated significantly with organ damage. Measurement of RI in addition to low-grade albuminuria is reportedly useful for target organ damage screening in patients with resistant Blood pressure variability and renal function T Kawai et al hypertension. 10 RI values were independently correlated with carotid intima-media thickness in patients with never-treated essential hypertension 9 and metabolic syndrome. 8 These results suggest that renal vascular resistance indicated by the RI reflects the degree of systemic atherosclerosis, and that RI can serve as a useful marker to detect and evaluate atherosclerotic diseases due to cardiovascular diseases risk factors, such as hypertension, DM, dyslipidemia and metabolic syndrome. Previously, a very interesting investigation was reported concerning the relationship between RI and histopathological analysis by renal biopsy, including glomerular sclerosis, interstitial fibrosis/tubular atrophy, interstitial infiltration and arteriolosclerosis. By stepwise multiple regression analysis, only arteriolosclerosis was found to be an independent risk factor for increased RI. 25 Therefore, the results of our study showing the correlation between visit-to-visit variability in BP and RI indicate that visit-to-visit variability in SBP is an independent risk factor for renal arteriosclerotic change, and could be a useful predictor of renal dysfunction.
Multivariate analysis revealed that variability in SBP was significant risk factors for higher RI independent of not only other renal risk factors, but also eGFR and albuminuria. It indicated that employing variability in SBP in addition to eGFR and albuminuria to evaluate renal arteriosclerotic change is convenient and efficacious in clinical practice.
Previous reports suggest that DBP variability is independently predictive of nephropathy, but not of retinopathy, in DM patients. 26 We found very similar results in hypertensive patients. In this study, variability in BP correlated significantly with the level of proteinuria and RI, but not with eGFR; although eGFR calculated easily from serum creatinine level, age and sex is useful for renal function screening, it is generally difficult to assess the pathogenesis of CKD using only eGFR. We previously reported that the RI might be a more sensitive parameter for the evaluation of very early renal vascular damage than eGFR, 17 so we thought that RI could detect early renal damage correlated with variability in BP more sensitively than eGFR, and that this is the reason why higher variability in SBP was significantly correlated with higher RI and higher prevalence rate of clinical albuminuria and microalbuminuria, but not with eGFR.
Based on previous large clinical trials, mean BP is widely recognized to correlate strongly with cardiovascular diseases, including CKD, and clinical guidelines recommend using mean BP for diagnosis and management of hypertension to prevent cardiovascular event. This study suggests that visit-to-visit variability in BP should be considered a new therapeutic target for renal protection independent of mean BP.
Rothwell et al. 27 reported that calcium channel blocker and bblockers had different effects on variability of BP. In this study, however, there were no differences according to the type of antihypertensive agent (angiotensin receptor blockers, angiotensin-converting enzymes inhibitors, calcium channel blocker, diuretics, b-blockers, ablockers or aldosterone blockers). One explanation for this is that most of our subjects were receiving two or more different antihypertensive agents. Therefore, studies comparing each antihypertensive agent independently are necessary to evaluate their renoprotective effects.
Compared with lower s.d. in SBP group, higher s.d. in SBP group showed significantly higher RI, lower DBP and higher prevalence rate of type 2 DM. With aging or atherosclerotic disease, the arterial wall is generally stiffening, and the elasticity reduces; thus, DBP lowers and the pulse pressure rises. [28] [29] The decrease in DBP is thought to reflect vascular damage and increased risk of atherosclerosis. Therefore, the vascular damage induced by cardiovascular risk factors such as DM and hypertension is thought to be correlated with variability in BP.
We showed that subjects with higher variability in SBP from three BP measurements also showed a significantly higher RI with lower decision correlation. In clinical setting, the BP variability calculated from few outpatient visits is thought to be more convenient and easy-to-use index to assess the arteriosclerotic change of patients, although for more accurate assessments we could take more BP measurements in account.
Study limitations
This study has several limitations. First, our study was observational and cross-sectional. Longitudinal, prospective studies are necessary to evaluate the utility of measuring variability in BP for predicting the Blood pressure variability and renal function T Kawai et al progression of atherosclerotic diseases and renal prognosis. Second, our sample size was relatively small. Third, because patients were recruited at the university hospital in this study, most patients had already been under medical treatment for hypertension, dyslipidemia and diabetes at the time of investigation; therefore, several parameters such as BP, lipid profile and glycosylated hemoglobin, hemoglobin A1c might have been influenced by medical treatment.
Conclusion
In conclusion, this study documents the impact of variability in BP on renal function. Visit-to-visit variability in BP is correlated significantly with renal function evaluated by the RI and albuminuria. This parameter could be a useful predictor of renal dysfunction and should be considered as a therapeutic target for renal protection.
